In a report released today, Adam Evertts PhD from LifeSci Capital reiterated a Buy rating on MEI Pharma (MEIP), with a price target of $9.00. The company’s shares closed last Wednesday at $2.74.
PhD has an average return of 0.4% when recommending MEI Pharma.
According to TipRanks.com, PhD is ranked #4800 out of 7073 analysts.
Currently, the analyst consensus on MEI Pharma is a Strong Buy with an average price target of $9.50, implying a 234.5% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
See today’s analyst top recommended stocks >>
Based on MEI Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $25.5 million and GAAP net loss of $18.48 million. In comparison, last year the company earned revenue of $1.13 million and had a net profit of $3.05 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
